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The epidemiology of high blood pressure (BP) in the
community has relied on conventional readings utilizing
cuff-based measurements of the brachial artery. Beyond
establishing relationships between BP and major clinical
events, clinical trials have provided data regarding the levels
of BP at which antihypertensive treatment can reduce
adverse cardiovascular outcomes. Now, beyond these
approaches, a paper in this issue of the Journal by Chen et al.
(1) provides valuable background data for central BP.See page 1780Can central BP enhance clinical practice? The principal
phenotype of hypertension in the aging population is linked
to the hemodynamic effects of aortic stiffening, so, central
BP analyses could provide valuable guidance in under-
standing and managing this common condition.
Central (aortic) BP is an enticing concept. The 3 major
target organs of hypertensiondthe central nervous system;
the heart, including both the left ventricle and the coronary
circulation; and the kidneysdare connected to the aorta. It
has been observed that BP readings in the brachial artery
are not exactly representative of central BP because of an
ampliﬁcation effect that augments the peripheral BP (2,3).
Moreover, the degree of augmentation varies considerably
among individuals (4,5). All the same, we cannot be certain
that the arteries linking the central circulation to these
organs are not affected by adaptive processes that could also
result in BPs that differ from the aortic readings. Indeed, the*Editorials published in the Journal of the American College of Cardiology reﬂect the
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American College of Cardiology.
From the yDivision of Cardiovascular Medicine, State University of New York,
Downstate College of Medicine, Brooklyn, New York; and the zDivision of
Nephrology, Department of Medicine, Penn Hypertension Program, University of
Pennsylvania, Philadelphia, Pennsylvania. Dr. Weber is a member of the Speakers’
Bureau for Daiichi Sankyo, Forest Pharmaceuticals, and Takeda Pharmaceuticals; and
serves as a consultant for Boehringer Ingelheim, Daiichi Sankyo, Forest Pharmaceu-
ticals, and Takeda Pharmaceuticals. Dr. Townsend is a consultant for Medtronic and
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powerful autoregulatory processes that modify internal BP.
A study that has drawn strong attention to the potential
superiority of central BP is the CAFE (Conduit Artery
Function Evaluation) substudy of the ASCOT (Anglo
Scandinavian Cardiac Outcomes Trial) (6). The main
ASCOT trial originally reported that the calcium channel
blocker, amlodipine, had superior cardiovascular stroke and
survival beneﬁts to the beta-blocker, atenolol, despite
apparently similar effects of these drugs on arm BP. In the
CAFE substudy, despite nearly identical effects of the drugs
on brachial BP, amlodipine had a signiﬁcantly greater effect
than atenolol in reducing central BP, thus suggesting that
this BP value was the pivotal factor in cardiovascular
protection (6). The practical importance of this observation,
however, had been somewhat diminished because although
the antihypertensive action of the conventional beta-blocker
atenolol, as with other conventional beta-blockers (7), was
clearly less in the central circulation than at the brachial
artery, this ﬁnding does not seem to apply to newer vaso-
dilating agents in this class (7) and does not appear to have
been observed with other antihypertensive classes.
Building on studies such as CAFE, central BP values have
been more predictive of vascular disease and major clinical
events than brachial BP in several studies (8,9) and offer the
opportunity of reﬁning our estimation of cardiovascular risk.
One obstacle in the more widespread usage of this technique
is the need for reference standards.
Establishing thresholds. If central BP is to play a part in
the diagnosis and therapy of hypertension, it is critical to
establish criteria for guiding clinical decisions. The new
report by Chen et al. (1) seeks to address this need. The
work of these investigators is based on prospective longitu-
dinal studies of central BPs in 2 independently recruited
cohorts of volunteers in Taiwan. The ﬁrst of these was
a derivation cohort from which diagnostic thresholds were
established, and the second was a validation cohort in which
the ﬁndings from the ﬁrst cohort could be tested further.
The derivation cohort was composed of subjects who,
using standard BP methods, were normotensive or, if
hypertensive, were not receiving treatment. They were aged
between 30 and 79 years. Subjects were excluded if they had
a history of cardiovascular or stroke events. The validation
cohort was slightly older (a mean age of 54 vs. 52 years in the
derivation cohort), had lower arm and central BP values, and
had a greater prevalence of dyslipidemia. The central BPs
were measured by a method based on carotid tonometry in
the derivation cohort and by radial artery tonometry using
a generalized transfer function in the validation cohort. The
main endpoint of the study was mortality and its causes.
This was assessed by matching the databases of the 2 cohorts
with the National Death Registry in Taiwan.
Based on sophisticated statistical modeling, the authors
propose that optimal central BP be 110/80 mm Hg and that
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these values, they reported highly signiﬁcant hazard ratios
based on systolic BPs for cardiovascular death, total death,
and stroke death. By comparison, the use of systolic BPs
measured in the brachial artery was predictive of total death
and stroke death, but not cardiovascular death.
Interpreting the ﬁndings. There should be some care in
generalizing the ﬁndings of this research. These observations
were conducted in Taiwanese subjects, and it would be useful
to obtain conﬁrmatory evidence in other populations.
Furthermore, the subjects did not have known clinical
cardiovascular disease, which is acceptable in describing the
natural history of BP values, but not necessarily relevant to
patients in clinical practice. The endpoints for the study were
all related to mortality, an understandable limitation, given
the fact that event rates were obtained from a death registry.
All the same, it is quite possible that nonfatal coronary,
stroke, and renal ﬁndings might depend on different central
BP thresholds.
Another issue with central BP is the proliferation of
measurement devices. Even in the paper by Chen et al. (1),
2 different methods were used, although each of them has
been validated (10,11). Apart from intrinsic variations in the
measurements provided by different instruments, some of
themdparticularly those depending on applanation tono-
metrydare operator dependent, and so require skill and
experience. The cuff methods that are used for central BP
use oscillometric technology, which again requires care and
consistency in their use. In addition, most methods depend
on obtaining peripheral pulse waves that are then translated
into central BPs by proprietary algorithms. Although the
results may be reproducible for a given device, variations
between instruments may make it difﬁcult to compare their
data. It should be acknowledged that this problem is not
unique to central BP. Conventional ofﬁce readings, either
manual or by automated monitors, are also subject to
between-method variability.
Finding a clinical context. The work by Chen et al. (1) in
establishing thresholds is a vital step in a broader use of
central BP in research and in clinical practice. This new
information is reminiscent of the Prospective Studies
Collaboration that links conventional ofﬁce BPs to coronary
and stroke mortality (12). In that database, the lowest event
rates were at 115/75 mm Hg and doubled with each 20/10
mm Hg increment after that. But although these data help
in describing the natural history of people with high BP,
they have limited clinical applicability. Simply put, they
describe the outcomes of naturally found BPs, but cannot
inform us whether reducing BP in hypertensive patients will
produce the low event rates predicted by the epidemiology.
Because of this uncertainty, major guidelines pragmati-
cally deﬁne hypertension as that level of BP at which there is
clinical trial evidence that therapeutic interventions reducecardiovascular event rates (13,14). Based on conventional
readings, there is evidence of beneﬁt when systolic BPs are
reduced from above to below 160 mm Hg (15) and from
above to below 150 mm Hg (16). Ironically, the most widely
recommended threshold of 140 mm Hg has not been based
on prospective clinical trials designed to test this value, but
analysis of on-treatment cardiovascular, stroke, and renal
event rates in several authoritative studies has indicated
outcomes beneﬁts when systolic BP is reduced below 140
mm Hg (17–19). Further reduction below 130 mm Hg, the
central BP threshold suggested by Chen et al. (1), appears to
be safe but has not been shown to provide further beneﬁt.
How can the new central BP thresholds be used?
Ongoing randomized clinical trials with cardiovascular
outcomes to test the validity of 130 mm Hg or other
threshold values during hypertension therapy will be critical
in conﬁrming the role of central BP. Additionally, prospec-
tive therapeutic trials that relate central BPs to carefully
selected surrogate vascular endpoints could build a portfolio
of evidence to further advance interpretation of central BPs.
Even so, we believe we are now at a point where central BP
should emerge, not only as a key endpoint in research studies,
but also as a measurement of growing interest and value to
clinicians.
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